Trial Profile
A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 03 May 2018 Status changed from active, no longer recruiting to completed.
- 09 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Apr 2018.
- 05 Apr 2017 Results from NCT02293993 and NCT02197676 studies evaluating integrated molecular profiles and guadecitabine response in relapsed/refractory acute myeloid leukemia, presented at the 108th Annual Meeting of the American Association for Cancer Research